Medtronic is back in the news this week as new data suggests that one of their products, when used in high doses during spinal fusion procedures, may actually increase a patient’s risk for developing cancer.

The information, which was presented during a recent national meeting of spinal surgeons, was given to the FDA by Medtronic when the company sought approval to sell a high-strength version of an already existing bone growth product known as Infuse. However, based on the results of the study, the FDA subsequently rejected Medtronic’s high-dose product, which was called Amplify, due to concerns over the increased cancer risks.

The study’s data regarding the higher-dose formulation (Amplify) also revealed potential implications for patients who have previously received Infuse, as both products contain the same active ingredient. In response to the controversy surrounding the wide-spread use of Infuse, Medtronic issued a $2.5 million grant to Yale University for the purpose of conducting an independent review of all data associated with the efficacy and safety of Infuse.

RESULTS & SETTLEMENTS

Frank M. Eidson P.A. has been tirelessly representing the rights of Central Florida victims since 1989.

$4.2 Million

Auto Accident

$2.3 Million

Workers Comp Case

$5.65 Million

Auto Accident


Free, No Obligation Case Review.

Fill out our contact form below for your free, no obligation case review.

  • This field is for validation purposes and should be left unchanged.

Help provide wounded servicemen and women with therapeutic outdoor adventures. Like our Facebook page and we'll contribute $1 to Wounded Warriors Outdoors.

Contact Our Orlando Attorney

If you have been injured in an accident, turn to Frank M. Eidson P.A. Whether your case is a simple collision or a complicated auto wrongful death case, contact personal injury lawyer Frank Eidson today to schedule your free consultation.

407-245-2887